SCHEMBL3129190

SCHEMBL3129190

COc1ccc(N(Cc2c(F)cccc2F)c2cccc(C(=O)O)c2)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
RAB9A P51151 2/20 0.47
HTT P42858 2/20 0.47
MAPK1 P28482 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA7 P43166 1/20 0.47
TPMT P51580 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MRGPRX4 Q96LA9 3/20 0.46
MEP1B Q16820 3/20 0.45
ALDH1A1 P00352 2/20 0.43
TSHR P16473 2/20 0.43
PPARA Q07869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3126269 0.92 TSHR (0.48) LMNARAB9AHTTMAPK1CA12
SCHEMBL3129354 0.92 RXRA (0.43) LMNARAB9AHTTMAPK1CA12
SCHEMBL3129663 0.92 HTT (0.41) LMNARAB9AHTTMAPK1CA12
SCHEMBL3123339 0.88 PDE4B (0.58) PDE4APDE4BPDE4CPDE4D
SCHEMBL4202300 0.88 PDE4B (0.60) PDE4APDE4BPDE4CPDE4D
SCHEMBL3211763 0.86 MEN1 (0.40) LMNAMEN1KMT2AALDH1A1TSHR
SCHEMBL3121009 0.84 PDE4A (0.42) MRGPRX4MEP1BPPARAPDE4APDE4B
SCHEMBL3128367 0.84 MRGPRX4 (0.49) CA12CA1CA2CA4CA6
SCHEMBL3123468 0.84 PDE4D (0.51) PDE4APDE4BPDE4CPDE4D
SCHEMBL3131220 0.83 PDE4D (0.52) KMT2AMEP1BPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B LMNA 3769/4885RAB9A 2160/4885HTT 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.